If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Control of blood pressure in perioperative hypertension, i.e. hypertension associated with surgical procedures, especially cardiovascular procedures, such as the hypertension seen during intratracheal intubation, anaesthesia, skin incision, sternotomy, cardiac bypass and in the immediate post-surgical period.
Congestive heart failure associated with acute myocardial infarction.
Treatment of angina pectoris in patients who have not responded to recommended doses of organic nitrates and/or a beta blocker.
Production of controlled hypotension during neurosurgical and orthopaedic surgical procedures.
Severe arterial hypotension with bradycardia has been reported in patients who received intravenous glyceryl trinitrate within the first 24 hours after myocardial infarction
Alcohol intoxication has been reported in patients receiving high dose intravenous infusions
methaemoglobinaemia
anaphylaxis
exfoliative dermatitis
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
Cardiogenic shock, in so far as sufficiently high left ventricular end-diastolic pressure is not ensured by intra-aortal counterpulsation or positive inotropic medicines.
Concomitant administration of glyceryl trinitrate with phosphodiesterase inhibitors type 5 (PDE5) used for the treatment of erectile dysfunction or pulmonary arterial hypertension, such as sildenafil, vardenafil, or tadalafil, which has been shown to potentiate the vasodilatory effects of glyceryl trinitrate, resulting in severe hypotension.
As a supplementary medication for obstructive cardiomyopathy, especially if it is associated with aortic or mitral stenosis or constrictive pericarditis as it has been shown that nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy.
Concomitant administration of a soluble guanylate cyclase (GC) stimulator, such as riociguat due to potentiation of hypotensive effects.